New study suggests early COVID-19 strain spread from bats by wildlife trade
SAN DIEGO (FOX 5/KUSI) — A recent study from an international team of researchers, including those from UC San Diego's School of Medicine, gives new credence to the theory that the COVID-19 pandemic spread naturally by way of wild mammal trade, as opposed to a lab leak.
The study, which was published in the science journal Cell on Wednesday, examined the evolution of the COVID-19 virus — SARS-CoV-2 — and compared it to a coronavirus behind an earlier outbreak, the 2002 SARS pandemic.
Using genome sequencing to map the histories of these and more than 250 coronaviruses, the scientists found a number parallels in the evolution of the viruses behind SARS and COVID that suggest the two shared a similar mode of dispersal.
Scripps Health announces extension of contract with Anthem Blue Cross
These findings, in their view, dispute the contested theory that COVID originated from a lab leak, even as the Trump administration and Congressional Republicans have ratcheted up promotion of supposition in recent months.
The ancestors of both viruses, the study says, had circulated in horseshoe bats across much of China and other countries in southeast Asia for millennia, mutating as it interacted with other coronaviruses inside the cells of its host.
This genetic mixing, which is called recombination, creates new variations of the virus, each more potent until it reaches the point where it can become a human pathogen.
The closest ancestor identified by the study to SARS and COVID reached that tipping point only a few years before it was reported by humans — about one to two years before SARS was first detected in Guangdong Province and five to seven years before COVID emerged in Wuhan.
However, the distance between the origin of this viral ancestor and where the pandemics began was too far to have been carried just by bats. Instead, the study says these viruses spilled over into other wild animals, which were unwittingly carried hundreds of miles by traders.
The consensus among researchers of the earlier SARS pandemic has generally agreed this is how the virus reached Guangdong relatively quickly, most likely having hitched a ride to animals like palm civets or raccoon dogs commonly traded for their fur and meat.
That patten of zoonotic spread, the new study argues, bolsters the plausibility that SARS-CoV2 reached Wuhan from southwest China in the same manner.
'For more than two decades the scientific community has concluded that the live-wildlife trade was how those hundreds of miles were covered,' said Dr. Michael Worobey, the head of the Department of Ecology and Evolutionary Biology at the University of Arizona who served as a co-senior author on the study. 'We're seeing exactly the same pattern with SARS-CoV-2.'
The researchers point to an earlier study they conducted that traced human transmission of COVID-19 back to the Huanan Seafood Market in Wuhan, where many wild mammals are sold by traders, as further evidence for natural zoonotic spillover.
'At the outset of the COVID-19 pandemic, there was a concern that the distance between Wuhan and the bat virus reservoir was too extreme for a zoonotic origin,' said Dr. Joel Wertheim, a professor of medicine at UCSD School of Medicine's Division of Infectious Diseases and Global Public Health and a co-senior author of the study.
Lawsuit filed against Aladdin Mediterranean Café amid ongoing salmonella investigation
'This paper shows that it isn't unusual and is, in fact, extremely similar to the emergence of SARS-CoV-1 in 2002,' he continued.
That said, proponents of the lab leak theory have pointed to this distance as proof of their explanation of COVID's early spread, arguing it must have been human intervention in the form of scientists that transported the coronavirus from southwest China to Wuhan.
However, no evidence has been provided that an earlier strain virus was in fact at the the Wuhan Institute of Virology, the lab at the center of the theory, before the pandemic.
While researchers concede the debate on COVID's origins may in all likelihood remain unsettled, the study's authors say their findings remain notable, giving researchers additional insight into a possible future coronavirus outbreak.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to FOX 5 San Diego & KUSI News.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
44 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.


Los Angeles Times
5 hours ago
- Los Angeles Times
COVID surges nationwide with highest rates in Southwest as students return to school
COVID-19 rates in the Southwestern United States reached 12.5% — the highest in the nation — according to new data from the U.S. Centers for Disease Control and Prevention released this week. Meanwhile, Los Angeles County recorded the highest COVID levels in its wastewater since February. The spike, thanks to the new highly contagious 'Stratus' variant, comes as students across California return to the classroom, now without a CDC recommendation that they receive updated COVID shots. That change in policy, pushed by Health and Human Services Secretary Robert F. Kennedy Jr., has been criticized by many public health experts. The COVID-19 virus, SARS-CoV-2, mutates often, learning to better transmit itself from person to person and evade immunity created by vaccinations and previous infections. The Stratus variant, first detected in Asia in January, reached the U.S. in March and became the predominant strain by the end of June. It now accounts for two-thirds of virus variants detected in wastewater in the U.S., according to the CDC. The nationwide COVID positivity rate hit 9% in early August, surpassing the January post-holiday surge, but still below last August's spike to 18%. Weekly deaths, a metric that lags behind positivity rates, has so far remained low. In May, RFK Jr. announced the CDC had removed the COVID vaccine from its recommended immunization schedule for healthy children and healthy pregnant women. The secretary argued it was the right move to reverse the Biden administration's policy, which in 2024, 'urged healthy children to get yet another COVID shot, despite the lack of any clinical data to support the repeat booster strategy in children.' That statement promptly spurred a lawsuit from a group of leading medical organizations — including the American Academy of Pediatrics, the American College of Physicians and the American Public Health Association — which argued the 'baseless and uninformed' decision violated federal law by failing to ground the policy on the recommendation of the scientific committee that looks at immunization practices in the U.S. The Advisory Committee on Immunization Practices has been routinely recommending updated COVID vaccinations alongside the typical yearly flu vaccination schedule. In its update for the fall 2024-spring 2025 season, it noted that in the previous year, a COVID booster decreased the risk of hospitalization by 44% and death by 23%. The panel argued the benefit outweighed isolated cases of heart conditions and allergic reactions associated with the vaccine. The panel also acknowledged that booster effectiveness decreases as new COVID strains — for which the boosters were not designed — emerge. Nevertheless, it still felt that most Americans should get booster shots. The CDC estimates that only about 23% of adults and 13% of children received the 2024-2025 COVID booster — even with the vaccine recommendation still in place. That's compared to roughly half of adults and children who received the updated flu shot in the same time frame.


USA Today
12 hours ago
- USA Today
Robert F. Kennedy Jr. declares 'loyalty' to Trump, rules out a 2028 presidential bid
WASHINGTON — Health and Human Services Secretary Robert F. Kennedy Jr. says he's not running for president in 2028 and intends to remain in his position until President Donald Trump leaves office. The leader of the "Make America Healthy Again" movement said in an X post that his "loyalty" lies with Trump, and he dismissed speculation about his political future as part of a "smear campaign" from disgruntled Washington insiders who oppose the MAHA agenda. "They're pushing the flat-out lie that I'm running for president in 2028. Let me be clear: I am not running for president in 2028," Kennedy said. Kennedy competed for the presidency in 2024, first as a Democrat and later as an independent, before suspending his candidacy last August and throwing his support behind Trump. After the election, Trump made him HHS secretary. His comments ruling out a 2028 bid came far-right activist Laura Loomer accused Kennedy aide Stefanie Spear of using her position at HHS to lay the groundwork for Kennedy to run again. Loomer's comment came in a Politico interview and followed an Axios report in July that said Kennedy super PAC head Tony Lyons and Spear convened MAHA supporters on a call that left some attendees with the impression he was mulling another campaign. But in his social media post, Kennedy said, "The president has made himself the answer to my 20-year prayer that God would put me in a position to end the chronic disease epidemic — and that's exactly what my team and I will do until the day he leaves office."